On March 31, 2026, a significant shift occurred in the landscape of venture capital as U.S. firms began to prioritize early investments in China's burgeoning biotech sector. This strategic pivot towards what is termed "upstream" investment reflects a proactive approach to securing promising biotech assets before the results of research are publicly disclosed. The move…
Read more
U.S. Venture Capitalists Embrace Early Investments in China’s Biotech Sector Amid Global Tensions



